Marshall Wace’s Taysha Gene Therapies TSHA Stock Holding History

Marshall Wace’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-476,865	Closed	-$1.56M	–	3488
2025 Q3	$1.56M	Buy	476,865 +397,367	+500%	+$1.13M	﹤0.01%	1731
2025 Q2	$184K	Buy	+79,498	New	+$173K	﹤0.01%	2470
2025 Q1	–	Sell	-138,111	Closed	-$239K	–	3101
2024 Q4	$239K	Sell	138,111 -347,915	-72%	-$722K	﹤0.01%	2301
2024 Q3	$977K	Sell	486,026 -300,068	-38%	-$658K	﹤0.01%	1660
2024 Q2	$1.76M	Sell	786,094 -244,563	-24%	-$712K	﹤0.01%	1438
2024 Q1	$2.96M	Buy	+1,030,657	New	+$2.15M	﹤0.01%	1201
2023 Q1	–	Sell	-69,296	Closed	-$157K	–	3111
2022 Q4	$157K	Buy	+69,296	New	+$140K	﹤0.01%	2730
2022 Q3	–	Sell	-91,670	Closed	-$341K	–	3803
2022 Q2	$341K	Sell	91,670 -47,716	-34%	-$189K	﹤0.01%	2973
2022 Q1	$909K	Buy	139,386 +81,028	+139%	+$606K	﹤0.01%	2495
2021 Q4	$679K	Buy	+58,358	New	+$880K	﹤0.01%	2651

Other funds holding TSHA

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace's TSHA Position: Q4 2025 in Review

Marshall Wace sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 476,865 shares — an estimated $1.56M sold.

Marshall Wace first reported a position in TSHA in Q4 2021 and held it in 10 quarters. The position peaked at $2.96M in Q1 2024. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

Marshall Wace reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 476,865 Taysha Gene Therapies shares in Q4 2025, an estimated $1.56M.
Marshall Wace first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 10 quarters.
Marshall Wace's Taysha Gene Therapies position peaked at $2.96M in Q1 2024.
195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.